Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLR-Matured Dendritic Cell Vaccination in Melanoma
NCT00940004Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2009
- Primary completion
- Nov 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mRNA-electroporated dendritic cell product in melanoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Toxicity of TLR-matured DC at 3 years and Immunological response upon vaccination with TLR-matured DC at 3 years. Started Jun 2009; status: completed.
02
Drugs
mRNA-electroporated dendritic cell product
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00940004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940004.